{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:19:16Z","timestamp":1788538756288,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03520-5","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:47:11Z","timestamp":1788536831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced Bisoprolol Oral Liquid Formulations for Flexible Pediatric and Geriatric Pharmacotherapy"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-2459","authenticated-orcid":false,"given":"Mar\u00eda Alejandra","family":"Operto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9399-5366","authenticated-orcid":false,"given":"Marina","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-8815","authenticated-orcid":false,"given":"Rub\u00e9n","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-3570","authenticated-orcid":false,"given":"Dar\u00edo","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1115-1715","authenticated-orcid":false,"given":"Silvana","family":"Vignaduzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"3520_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5863\/1551-6776-29.1.22","volume":"29","author":"RS Meyers","year":"2024","unstructured":"Meyers RS. The past, present, and future of oral dosage forms for children. J Pediatr Pharmacol Ther. 2024;29:22\u201331. https:\/\/doi.org\/10.5863\/1551-6776-29.1.22.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"3520_CR2","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1208\/s12249-018-0992-5","volume":"19","author":"M Morri","year":"2018","unstructured":"Morri M, Castellano P, Leonardi D, Vignaduzzo S. First development, optimization, and stability control of a pediatric oral atenolol formulation. AAPS PharmSciTech. 2018;19:1781\u20138. https:\/\/doi.org\/10.1208\/s12249-018-0992-5.","journal-title":"AAPS PharmSciTech"},{"key":"3520_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1208\/s12249-020-01768-z","volume":"21","author":"M Morri","year":"2020","unstructured":"Morri M, Casabonne C, Leonardi D, Vignaduzzo S. Orphan formulations for pediatric use: development and stability control of two sildenafil citrate solutions for the treatment of pulmonary hypertension. AAPS PharmSciTech. 2020;21:221. https:\/\/doi.org\/10.1208\/s12249-020-01768-z.","journal-title":"AAPS PharmSciTech"},{"key":"3520_CR4","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-025-03262-w","volume":"27","author":"M Morri","year":"2025","unstructured":"Morri M, Operto MA, Maggio R, Leonardi D, Vignaduzzo S. The influence of pH and preservative agents on physicochemical and microbiological stability of a flexible dose\/age-appropriate formulation of enalapril maleate. A quality by design\u2011based optimization. AAPS PharmSciTech. 2025;27:17. https:\/\/doi.org\/10.1208\/s12249-025-03262-w.","journal-title":"AAPS PharmSciTech"},{"key":"3520_CR5","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/pharmaceutics15041306","volume":"15","author":"C-M J\u00eetc\u0103","year":"2023","unstructured":"J\u00eetc\u0103 C-M, J\u00eetc\u0103 G, \u0150sz B-E, Pu\u0219ca\u0219 A, Imre S. Stability of oral liquid dosage forms in pediatric cardiology: a prerequisite for patient\u2019s safety-a narrative review. Pharmaceutics. 2023;15:1306. https:\/\/doi.org\/10.3390\/pharmaceutics15041306.","journal-title":"Pharmaceutics"},{"key":"3520_CR6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3390\/children9040488","volume":"9","author":"W Malkawi","year":"2022","unstructured":"Malkawi W, AlRafayah E, AlHazabreh M, AbuLaila S, Al-Ghananeem A. Formulation challenges and strategies to develop pediatric dosage forms. Children (Basel). 2022;9:488. https:\/\/doi.org\/10.3390\/children9040488.","journal-title":"Children (Basel)"},{"key":"3520_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1208\/s12249-023-02612-w","volume":"24","author":"MA Operto","year":"2023","unstructured":"Operto MA, Maggio R, Leonardi D, Vignaduzzo S. Flexible new dosage forms containing carvedilol for the treatment of patients with cardiovascular disorders: development, stability, palatability, and microbiological studies. AAPS PharmSciTech. 2023;24:159. https:\/\/doi.org\/10.1208\/s12249-023-02612-w.","journal-title":"AAPS PharmSciTech"},{"key":"3520_CR8","doi-asserted-by":"publisher","unstructured":"Kumari A, Aggarwal G, Kaur A. Applications of quality by design in pharmaceutical product development lifecycle. In: Jain NK, Bajwa N, editors. Introduction to quality by design (QbD). Singapore: Springer Nature Singapore; 2024. p. 419\u201353. https:\/\/doi.org\/10.1007\/978-981-99-8034-5_15.","DOI":"10.1007\/978-981-99-8034-5_15"},{"key":"3520_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1208\/s12249-022-02447-x","volume":"23","author":"E de Saldanha Simon","year":"2022","unstructured":"de Saldanha Simon E, Wingert NR, Gobetti C, Primieri GB, Ayres MV, de Almeida SHO, et al. Development, quality by design-based optimization, and stability assessment of oral liquid formulations containing baclofen for hospital use. AAPS PharmSciTech. 2022;23:301. https:\/\/doi.org\/10.1208\/s12249-022-02447-x.","journal-title":"AAPS PharmSciTech"},{"key":"3520_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40005-022-00575-x","volume":"52","author":"S-H Lee","year":"2022","unstructured":"Lee S-H, Kim J-K, Jee J-P, Jang D-J, Park Y-J, Kim J-E. Quality by design (QbD) application for the pharmaceutical development process. J Pharm Investig. 2022;52:649\u201382. https:\/\/doi.org\/10.1007\/s40005-022-00575-x.","journal-title":"J Pharm Investig"},{"key":"3520_CR11","doi-asserted-by":"publisher","first-page":"132824","DOI":"10.1016\/j.ijcard.2024.132824","volume":"417","author":"ANLC Seng","year":"2024","unstructured":"Seng ANLC, Leong LY, Yunus NM, Phang KK, Daniel YTW, Tan MM, et al. The use of bisoprolol in treatment for heart failure and its effects of dose titration on blood pressure and heart rate. Int J Cardiol. 2024;417:132824. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132824.","journal-title":"Int J Cardiol"},{"key":"3520_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2016.10.046","volume":"226","author":"S Toyoda","year":"2017","unstructured":"Toyoda S, Haruyama A, Inami S, Amano H, Arikawa T, Sakuma M, et al. Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure. Int J Cardiol. 2017;226:71\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2016.10.046.","journal-title":"Int J Cardiol"},{"key":"3520_CR13","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/jps.23817","volume":"103","author":"NA Charoo","year":"2014","unstructured":"Charoo NA, Shamsher AAA, Lian LY, Abrahamsson B, Cristofoletti R, Groot DW, et al. biowaiver monograph for immediate-release solid oral dosage forms: Bisoprolol fumarate. J Pharm Sci. 2014;103:378\u201391. https:\/\/doi.org\/10.1002\/jps.23817.","journal-title":"J Pharm Sci"},{"key":"3520_CR14","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1161\/01.CIR.99.21.2829","volume":"99","author":"RJ Gibbons","year":"1999","unstructured":"Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al. ACC\/AHA\/ACP\u2013ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. Circulation. 1999;99:2829\u201348. https:\/\/doi.org\/10.1161\/01.CIR.99.21.2829.","journal-title":"Circulation"},{"key":"3520_CR15","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1253\/circj.CJ-18-1199","volume":"83","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui H, Momomura S, Masuyama T, Saito Y, Komuro I, Murohara T, et al. Tolerability, efficacy, and safety of bisoprolol vs. carvedilol in Japanese patients with heart failure and reduced ejection fraction - The CIBIS-J trial. Circ J. 2019;83:1269\u201377. https:\/\/doi.org\/10.1253\/circj.CJ-18-1199.","journal-title":"Circ J"},{"key":"3520_CR16","unstructured":"Comit\u00e9 de Medicamentos de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Bisoprolol. Pediam\u00e9cum. 2015. \/pediamecum\/principios-activos\/bisoprolol."},{"key":"3520_CR17","doi-asserted-by":"publisher","first-page":"5.2","DOI":"10.1136\/archdischild-2023-NPPG.9","volume":"108","author":"A Bueno Gomez","year":"2023","unstructured":"Bueno Gomez A, Healy M, Delle Donne G, Bentley S, Makhecha S, Daubeney P, et al. P10 initiation of bisoprolol in paediatric patients - experience from a specialist paediatric cardiac centre. Arch Dis Child. 2023;108:5.2-6. https:\/\/doi.org\/10.1136\/archdischild-2023-NPPG.9.","journal-title":"Arch Dis Child"},{"key":"3520_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.legalmed.2012.09.004","volume":"15","author":"M Hashiyada","year":"2013","unstructured":"Hashiyada M, Usui K, Hayashizaki Y, Hosoya T, Igari Y, Sakai J, et al. Unexpectedly high blood concentration of bisoprolol after an incorrect prescription: a case report. Leg Med Tokyo. 2013;15:103\u20135. https:\/\/doi.org\/10.1016\/j.legalmed.2012.09.004.","journal-title":"Leg Med Tokyo"},{"key":"3520_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ajem.2020.09.057","volume":"39","author":"A Nozaki","year":"2021","unstructured":"Nozaki A, Kobayashi T, Naruhashi K, Okugawa H, Horiuchi N, Nakanishi H, et al. An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms. Am J Emerg Med. 2021;39:146\u201350. https:\/\/doi.org\/10.1016\/j.ajem.2020.09.057.","journal-title":"Am J Emerg Med"},{"key":"3520_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s44446-026-00071-5","volume":"34","author":"MA Ibrahim","year":"2026","unstructured":"Ibrahim MA, Almutairi SK, Mahrous GM. Optimization and evaluation of different fast acting tablet formulations containing bisoprolol fumarate. Saudi Pharm J. 2026;34:20. https:\/\/doi.org\/10.1007\/s44446-026-00071-5.","journal-title":"Saudi Pharm J"},{"key":"3520_CR21","doi-asserted-by":"publisher","first-page":"115096","DOI":"10.1016\/j.ejpb.2026.115096","volume":"224","author":"BL Camboim","year":"2026","unstructured":"Camboim BL, Bersagui BS, de Oliveira Almeida SH, Ayres MV, Loureiro Mendez AS, Garcia CV. Development of levothyroxine sodium pediatric oral solution driven by STEP database: Stability study and degradation products by LC-MS. Eur J Pharm Biopharm. 2026;224:115096. https:\/\/doi.org\/10.1016\/j.ejpb.2026.115096.","journal-title":"Eur J Pharm Biopharm"},{"key":"3520_CR22","doi-asserted-by":"publisher","first-page":"114801","DOI":"10.1016\/j.ejpb.2025.114801","volume":"214","author":"R Desquines","year":"2025","unstructured":"Desquines R, Ramjaun Z, Jaafar A, Brouillet F, Cavalie S, Jamme T, et al. Optimization and stability evaluation of a pediatric spironolactone oral suspension: Formulation development and analytical validation. Eur J Pharm Biopharm. 2025;214:114801. https:\/\/doi.org\/10.1016\/j.ejpb.2025.114801.","journal-title":"Eur J Pharm Biopharm"},{"key":"3520_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1208\/s12249-017-0902-2","volume":"19","author":"S Narasimha Murthy","year":"2018","unstructured":"Narasimha Murthy S, Repka MA. Excipient stability: a critical aspect in stability of pharmaceuticals. AAPS PharmSciTech. 2018;19:11\u201311. https:\/\/doi.org\/10.1208\/s12249-017-0902-2.","journal-title":"AAPS PharmSciTech"},{"key":"3520_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1208\/s12249-017-0866-2","volume":"19","author":"A Patil","year":"2018","unstructured":"Patil A, Bhide S, Bookwala M, Soneta B, Shankar V, Almotairy A, et al. Stability of organoleptic agents in pharmaceuticals and cosmetics. AAPS PharmSciTech. 2018;19:36\u201347. https:\/\/doi.org\/10.1208\/s12249-017-0866-2.","journal-title":"AAPS PharmSciTech"},{"key":"3520_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12877-019-1337-2","volume":"19","author":"E Belissa","year":"2019","unstructured":"Belissa E, Vallet T, Laribe-Caget S, Chevallier A, Chedhomme F-X, Abdallah F, et al. Acceptability of oral liquid pharmaceutical products in older adults: palatability and swallowability issues. BMC Geriatr. 2019;19:344. https:\/\/doi.org\/10.1186\/s12877-019-1337-2.","journal-title":"BMC Geriatr"},{"key":"3520_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s13346-022-01239-x","volume":"13","author":"SM El-Masry","year":"2023","unstructured":"El-Masry SM, Helmy SA, Helmy SAM, Mazyed EA. Patient-friendly extemporaneous formulation of bisoprolol: application to stability and bioavailability studies. Drug Deliv Transl Res. 2023;13:795\u2013810. https:\/\/doi.org\/10.1007\/s13346-022-01239-x.","journal-title":"Drug Deliv Transl Res"},{"key":"3520_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/jpps.2025.15387","author":"L Dubois","year":"2025","unstructured":"Dubois L, Bouguergour C, Paoli-Lombardo R, Castera-Ducros C, Jean C, Fuchs M, et al. Compounding and stability studies of liquid oral formulations of beta-blockers (bisoprolol, betaxolol, and nadolol) for paediatric patients. J Pharm Pharm Sci. 2025. https:\/\/doi.org\/10.3389\/jpps.2025.15387.","journal-title":"J Pharm Pharm Sci"},{"key":"3520_CR28","doi-asserted-by":"publisher","first-page":"A19","DOI":"10.1136\/ejhpharm-2023-eahp.42","volume":"30","author":"H Linxweiler","year":"2023","unstructured":"Linxweiler H, Boventer J, Walter A, Kr\u00e4mer I. 3PC-022 Formulation and quality control of a bisoprolol 0.5 mg\/ml oral solution for paediatric use. Eur J Hosp Pharm. 2023;30:A19. https:\/\/doi.org\/10.1136\/ejhpharm-2023-eahp.42.","journal-title":"Eur J Hosp Pharm."},{"key":"3520_CR29","unstructured":"World Health Organization. Development of paediatric medicines: points to consider in formulation. Working document QAS\/24.950. 2025. https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/norms-and-standards\/current-projects\/qas24.950_paediatric_medicines.pdf."},{"key":"3520_CR30","unstructured":"EMA. ICH: Q 1 A (R2): Stability testing of new drug substances and products - Step 5. 2003. https:\/\/www.ema.europa.eu\/en\/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline."},{"key":"3520_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jpba.2009.10.021","volume":"52","author":"SJ Joshi","year":"2010","unstructured":"Joshi SJ, Karbhari PA, Bhoir SI, Bindu KS, Das C. RP-HPLC method for simultaneous estimation of bisoprolol fumarate and hydrochlorothiazide in tablet formulation. J Pharm Biomed Anal. 2010;52:362\u201371. https:\/\/doi.org\/10.1016\/j.jpba.2009.10.021.","journal-title":"J Pharm Biomed Anal"},{"key":"3520_CR32","unstructured":"ICH. VALIDATION OF ANALYTICAL PROCEDURES Q2(R2). 2023. https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q2(R2)_Guideline_2023_1130.pdf."},{"key":"3520_CR33","doi-asserted-by":"publisher","unstructured":"USP-NF. Rockville MUSP. USP Syrup. 2017. https:\/\/doi.org\/10.31003\/USPNF_M80250_01_01.","DOI":"10.31003\/USPNF_M80250_01_01"},{"key":"3520_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/jppr.1127","volume":"46","author":"RP Patel","year":"2016","unstructured":"Patel RP, Wanandy T, Zani R, Jose MD, Shastri M, Zaidi STR. Stability of trimethoprim in newly formulated liquid dosage form. J Pharm Pract Res. 2016;46:10\u20134. https:\/\/doi.org\/10.1002\/jppr.1127.","journal-title":"J Pharm Pract Res"},{"key":"3520_CR35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/jppr.1612","volume":"50","author":"DP Ellis","year":"2020","unstructured":"Ellis DP, Rozek T, Milne RW. Stability of a compounded oral liquid formulation of clopidogrel for infants. J Pharm Pract Res. 2020;50:321\u20138. https:\/\/doi.org\/10.1002\/jppr.1612.","journal-title":"J Pharm Pract Res"},{"key":"3520_CR36","doi-asserted-by":"publisher","unstructured":"USP. Microbiological examination of nonsterile products: Acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use. USP-NF Online. Rockville,MD: United States Pharmacopeia. 2015. https:\/\/doi.org\/10.31003\/USPNF_M98730_03_01.","DOI":"10.31003\/USPNF_M98730_03_01"},{"key":"3520_CR37","doi-asserted-by":"publisher","first-page":"104571","DOI":"10.1016\/j.jddst.2023.104571","volume":"86","author":"P Verma","year":"2023","unstructured":"Verma P, Yadav KS. Quality by design (QbD) enabled and Box-Behnken design assisted approach for formulation of tranexamic acid loaded stratum corneum lipid liposomes. J Drug Deliv Sci Technol. 2023;86:104571. https:\/\/doi.org\/10.1016\/j.jddst.2023.104571.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3520_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ipha.2023.10.004","volume":"2","author":"A Khan","year":"2024","unstructured":"Khan A, Naquvi KJ, Haider MF, Khan MA. Quality by design- newer technique for pharmaceutical product development. Intelligent Pharmacy. 2024;2:122\u20139. https:\/\/doi.org\/10.1016\/j.ipha.2023.10.004.","journal-title":"Intelligent Pharmacy"},{"key":"3520_CR39","doi-asserted-by":"publisher","unstructured":"Sridharan S, Kulshrestha AS, del Rosario KC. Patient-centric drug product design: rationale and practical considerations. In: Qiu Y, Chen Y, Zhang GGZ, Mantri RVLY, editors. Developing solid oral dosage forms. Third edit. New Jersey: Elsevier; 2026. p. 573\u201383. https:\/\/doi.org\/10.1016\/B978-0-443-34156-4.00034-0.","DOI":"10.1016\/B978-0-443-34156-4.00034-0"},{"key":"3520_CR40","unstructured":"EMA. Guideline on pharmaceutical development of medicines for paediatric use. 2013. https:\/\/www.tga.gov.au\/sites\/default\/files\/2024-07\/Guidelineonpharmaceuticaldevelopmentofmedicinesforpaediatric use .pdf."},{"key":"3520_CR41","unstructured":"ICH. Pharmaceutical Development Q8(R2). Current Step 4 version. 2009. https:\/\/database.ich.org\/sites\/default\/files\/Q8%28R2%29 Guideline.pdf."},{"key":"3520_CR42","doi-asserted-by":"publisher","first-page":"106915","DOI":"10.1016\/j.jddst.2025.106915","volume":"108","author":"CS Gurski","year":"2025","unstructured":"Gurski CS, Lazo REL, Gelinsk MA, Alves LA, Sovinsk MS, Sari MHM, et al. Quality by design applied to pediatric-friendly formulations: a scoping review-based manufacturing process mapping for solid dosage forms. J Drug Deliv Sci Technol. 2025;108:106915. https:\/\/doi.org\/10.1016\/j.jddst.2025.106915.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3520_CR43","doi-asserted-by":"publisher","first-page":"111940","DOI":"10.1016\/j.biopha.2021.111940","volume":"141","author":"T Waghule","year":"2021","unstructured":"Waghule T, Dabholkar N, Gorantla S, Rapalli VK, Saha RN, Singhvi G. Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): a risk based industrial approach. Biomed Pharmacother. 2021;141:111940. https:\/\/doi.org\/10.1016\/j.biopha.2021.111940.","journal-title":"Biomed Pharmacother"},{"key":"3520_CR44","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3390\/nu14071497","volume":"14","author":"\u0141J Walczak-Nowicka","year":"2022","unstructured":"Walczak-Nowicka \u0141J, Herbet M. Sodium benzoate\u2014harmfulness and potential use in therapies for disorders related to the nervous system: a review. Nutrients. 2022;14:1497. https:\/\/doi.org\/10.3390\/nu14071497.","journal-title":"Nutrients"},{"key":"3520_CR45","doi-asserted-by":"publisher","first-page":"101798","DOI":"10.1016\/j.rechem.2024.101798","volume":"11","author":"L Hejazi","year":"2024","unstructured":"Hejazi L, Mahboubi-Rabbani M, Mahdavi V, Alemi M, Khanniri E, Bayanati M. A critical review on sodium benzoate from health effects to analytical methods. Results Chem. 2024;11:101798. https:\/\/doi.org\/10.1016\/j.rechem.2024.101798.","journal-title":"Results Chem"},{"key":"3520_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/pharmaceutics16010119","volume":"16","author":"M Bobillot","year":"2024","unstructured":"Bobillot M, Delannoy V, Trouillard A, Kinowski JM, Sanchez-Ballester NM, Soulairol I. Potentially harmful excipients: State of the art for oral liquid forms used in neonatology and pediatrics units. Pharmaceutics. 2024;16:119. https:\/\/doi.org\/10.3390\/pharmaceutics16010119.","journal-title":"Pharmaceutics"},{"key":"3520_CR47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejps.2016.05.019","volume":"92","author":"AC van der Vossen","year":"2016","unstructured":"van der Vossen AC, van der Velde I, Smeets OSNM, Postma DJ, Vermes A, Koch BCP, et al. Design and stability study of an oral solution of amlodipine besylate for pediatric patients. Eur J Pharm Sci. 2016;92:220\u20133. https:\/\/doi.org\/10.1016\/j.ejps.2016.05.019.","journal-title":"Eur J Pharm Sci"},{"key":"3520_CR48","doi-asserted-by":"publisher","first-page":"121501","DOI":"10.1016\/j.ijpharm.2022.121501","volume":"616","author":"D Khan","year":"2022","unstructured":"Khan D, Kirby D, Bryson S, Shah M, Rahman MA. Paediatric specific dosage forms: Patient and formulation considerations. Int J Pharm. 2022;616:121501. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121501.","journal-title":"Int J Pharm"},{"key":"3520_CR49","doi-asserted-by":"publisher","first-page":"119140","DOI":"10.1016\/j.biopha.2026.119140","volume":"198","author":"EH Garc\u00eda","year":"2026","unstructured":"Garc\u00eda EH, Guzm\u00e1n DC, Brizuela NO, Herrera MO, Peraza AV, del Angel DS, et al. Novel theophylline oral drops for pediatric use and biological evaluation. Biomed Pharmacother. 2026;198:119140. https:\/\/doi.org\/10.1016\/j.biopha.2026.119140.","journal-title":"Biomed Pharmacother"},{"key":"3520_CR50","doi-asserted-by":"publisher","first-page":"108259","DOI":"10.1016\/j.jddst.2026.108259","volume":"120","author":"CS Gurski","year":"2026","unstructured":"Gurski CS, Sovinski MS, Alves FMS, Alves LA, Domingos EL, Rossa LS, et al. Compounded captopril suspensions for neonatal tube administration: formulation development, physicochemical, microbiological, and drug losses assessment. J Drug Deliv Sci Technol. 2026;120:108259. https:\/\/doi.org\/10.1016\/j.jddst.2026.108259.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3520_CR51","doi-asserted-by":"publisher","first-page":"121670","DOI":"10.1016\/j.ijpharm.2022.121670","volume":"618","author":"M Van der Veken","year":"2022","unstructured":"Van der Veken M, Brouwers J, Budts V, Lauwerys L, Pathak SM, Batchelor H, et al. Practical and operational considerations related to paediatric oral drug formulation: An industry survey. Int J Pharm. 2022;618:121670. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121670.","journal-title":"Int J Pharm"},{"key":"3520_CR52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1130-6343(07)75395-3","volume":"31","author":"A Fern\u00e1ndez Polo","year":"2007","unstructured":"Fern\u00e1ndez Polo A, Caba\u00f1as Poy MJ, Clemente Bautista S, Oliveras Arenas M, Castillo Salinas F, Hidalgo Albert E. Osmolalidad de las formas farmac\u00e9uticas orales l\u00edquidas en un hospital para su aplicaci\u00f3n en neonatos. Farm Hosp. 2007;31:311\u20134. https:\/\/doi.org\/10.1016\/S1130-6343(07)75395-3.","journal-title":"Farm Hosp"},{"key":"3520_CR53","unstructured":"European Medicines Agency. ICH Q1E Evaluation of stability data - Scientific guideline. 2003."},{"key":"3520_CR54","doi-asserted-by":"publisher","unstructured":"Kasagi\u0107 Vujanovi\u0107 I, Jeli\u0107 D, Antunovi\u0107 V, Jan\u010di\u0107 Stojanovi\u0107 B, Ivanovi\u0107 D. Stability study of amlodipine besylate and bisoprolol fumarate in aqueous solution. Contemp Mater. 2014;5. https:\/\/doi.org\/10.7251\/COMEN1402212V.","DOI":"10.7251\/COMEN1402212V"},{"key":"3520_CR55","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3109\/03639049509026631","volume":"21","author":"WA Dulin","year":"1995","unstructured":"Dulin WA. Degradation of bisoprolol fumarate in tablets formulated with dicalcium phosphate. Drug Dev Ind Pharm. 1995;21:393\u2013409. https:\/\/doi.org\/10.3109\/03639049509026631.","journal-title":"Drug Dev Ind Pharm"},{"key":"3520_CR56","doi-asserted-by":"publisher","unstructured":"Kasagi\u0107-Vujanovi\u0107 I, Stojanovi\u0107 BJ, Ivanovi\u0107 D. Monitoring of bisoprolol fumarate stability under different stress conditions. In: Badnjevic A, editor. IFMBE proceedings, vol. vol 62. Singapore: Springer; 2017. p. 415\u201324. https:\/\/doi.org\/10.1007\/978-981-10-4166-2_64.","DOI":"10.1007\/978-981-10-4166-2_64"},{"key":"3520_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2023.04.017","volume":"188","author":"S Stegemann","year":"2023","unstructured":"Stegemann S, Klingmann V, Reidemeister S, Breitkreutz J. Patient-centric drug product development: Acceptability across patient populations \u2013 Science and evidence. Eur J Pharm Biopharm. 2023;188:1\u20135. https:\/\/doi.org\/10.1016\/j.ejpb.2023.04.017.","journal-title":"Eur J Pharm Biopharm"},{"key":"3520_CR58","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.xphs.2023.01.029","volume":"112","author":"M Algorri","year":"2023","unstructured":"Algorri M, Cauchon NS, Christian T, O\u2019Connell C, Vaidya P. Patient-centric product development: A summary of select regulatory CMC and device considerations. J Pharm Sci. 2023;112:922\u201336. https:\/\/doi.org\/10.1016\/j.xphs.2023.01.029.","journal-title":"J Pharm Sci"},{"key":"3520_CR59","unstructured":"ICH. Guideline Q9 (R1) on quality risk management Step 5. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q9-r1-quality-risk-management-step-5-revision-2_en.pdf."},{"key":"3520_CR60","unstructured":"ICH. Pharmaceutical quality system Q10. 2008. https:\/\/database.ich.org\/sites\/default\/files\/Q10 Guideline.pdf."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03520-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03520-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:47:13Z","timestamp":1788536833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03520-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3520"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03520-5","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no declarations of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"263"}}